Kromek Regulatory News (KMK)

Kromek Group plc

Total Voting Rights

In conformity with the FCA's Disclosure and Transparency Rules, Kromek Group plc ("Kromek" or the "Company") confirms the following:

As at 1 June 2017 Kromek's issued share capital consists of 259,175,618 ordinary shares of 1 pence each ("Ordinary Shares"). The Company holds no Ordinary Shares in treasury and accordingly the total number of current voting rights in the Company is 259,175,618 Ordinary Shares.

The above figure may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.

1 June 2017

Enquiries:

About Kromek Group plc

Kromek Group plc is a UK technology company (global HQ in County Durham) and a leading developer of high performance radiation detection products based on cadmium zinc telluride ("CZT"). Using its core CZT technology, Kromek designs develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets.

The Group's products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.

The Group's business model provides a vertically integrated technology offering to customers, from the growth of CZT crystals to finished products or detectors, including software, electronics and application specific integrated circuits ("ASICs").

The Group has operations in the UK, Germany and US (California and Pennsylvania), and is selling internationally through a combination of distributors and direct OEM sales.

Currently, the Group has over a hundred full time employees across its global operations. Further information on Kromek Group is available at www.kromek.com.